[11]Guezour N, Soussi G, Brosseau S, et al. Grade 3-4 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better outcome: a ...
Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. Advances in experimental medicine and biology. 2014; (772)229-262.Larzabal L, Nguewa PA, Pio R, Blanco D, Sanchez B, Rodriguez MJ, et al. Overexpression of TMP...
21. Liao, J., et al., Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer, 2010. 9: p. 198. 22. Dong, X.Y., et al., Implication of snoRNAs U50 in human breast cancer. J Genet Genomics, 2009. 36(8): p. 447-54. 23. Dong, X.Y., et ...
[8]Saji Hisashi, Okada Morihito, Tsuboi Masahiro, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority t...
[8]Saji Hisashi, Okada Morihito, Tsuboi Masahiro, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399: 1607-1617. ...
[5]Doebele RC, et al. Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Integrated Analysis of Patients Enrolled in Three Trials (STARTRK-2, STARTRK-1 and ALKA-372-001). 2019 AACR. [6]The efficacy and safety of taletrectinib in patients with TKI-naïve or...
27. Griffith, S.D., et al.,Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.JCO Clin Cancer Inform, 2019.3: p. 1-13. ...
Non-small cell lung cancer (NSCLC), the leading cause of cancer-related deaths, is responsible for estimated 1.6 million deaths as of the year 20121,2. Lung adenocarcinoma is the most common type of NSCLC3, highlighting the urgent need for novel therapeutic approaches. ...
腺苷是一种在肿瘤微环境中高水平产生的代谢产物,主要通过在免疫细胞上表达的腺苷A2A受体(adenosine A2A receptor, A2AR)有效地抑制炎症组织中的免疫反应,抑制抗肿瘤免疫应答。
17. YANG M, HU X, TANG B, et al. Exploring the interplay between methylation patterns and non-coding RNAs in non-small cell lung cancer:implications for pathogenesis and therapeutic targets[J]. Heliyon, 2024,10(2...